(S)-6,7-二甲氧基-1,2,3,4-四氢-3-异喹啉羧酸盐酸盐 | 103733-66-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: (S)-6,7-二甲氧基-1,2,3,4-四氢-3-异喹啉羧酸盐酸盐
• 中文别名: 6,7-二甲氧基-S-1,2,3,4-四氢异喹啉-3-羧酸盐酸盐
• 英文名称: (S)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid
• 英文别名: (S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid；6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-3(S)-Carboxylic Acid；(3S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-ium-3-carboxylate
• CAS: 103733-66-0
• 化学式: C₁₂H₁₅NO₄
• mdl: MFCD06796546
• 分子量: 237.255
• InChiKey: BWYXEHBJIMGDEB-VIFPVBQESA-N

物化性质

• 沸点：
  434.8±45.0 °C(Predicted)
• 密度：
  1.232±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 储存条件：
  室温

SDS

Name:	(S)-6 7-Dimethoxy-1 2 3 4-Tetrahydro-3-Isoquinolinecarboxylic Acid Material Safety Data Sheet
Synonym:	None Known
CAS:	103733-66-0

Section 1 - Chemical Product MSDS Name:(S)-6 7-Dimethoxy-1 2 3 4-Tetrahydro-3-Isoquinolinecarboxylic Acid Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
103733-66-0	(S)-6,7-Dimethoxy-1,2,3,4-Tetrahydro-3	ca. 100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 103733-66-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 282 - 283 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H16ClNO4
Molecular Weight: 273.73

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 103733-66-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(S)-6,7-Dimethoxy-1,2,3,4-Tetrahydro-3-Isoquinolinecarboxylic Acid Hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 103733-66-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 103733-66-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 103733-66-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-6,7-二甲氧基-1,2,3,4-四氢-3-异喹啉羧酸盐酸盐 在 4-二甲氨基吡啶 、 氯化亚砜 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 (S)-methyl 2-(2-(4-chlorophenyl)acetyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
  参考文献：
  名称：

  Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold

  摘要：

  Direct inhibition of coagulation factor Xa (FXa) carries significant promise for developing effective and safe anticoagulants. Although a large number of FXa inhibitors have been studied, each can be classified as either possessing a highly flexible or a rigid core scaffold. We reasoned that an intermediate level of flexibility will provide high selectivity for FXa considering that its active site is less constrained in comparison to thrombin and more constrained as compared to trypsin. We studied several core scaffolds including 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid for direct FXa inhibition. Using a genetic algorithm-based docking and scoring approach, a promising candidate 23 was identified, synthesized, and found to inhibit FXa with a K-i of 28 mu M. Optimization of derivative 23 resulted in the design of a potent dicarboxamide 47, which displayed a K-i of 135 nM. Dicarboxamide 47 displayed at least 1852-fold selectivity for FXa inhibition over other coagulation enzymes and doubled PT and aPTT of human plasma at 17.1 mu M and 20.2 mu M, respectively, which are comparable to those of clinically relevant agents. Dicarboxamide 47 is expected to serve as an excellent lead for further anticoagulant discovery. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.06.032
• 作为产物：
  描述：

  (S)-2-氨基-3-(3,4-二甲氧基苯基)-2-甲基丙酸盐酸盐 在 盐酸 、 聚合甲醛 作用下， 以 磷酸酐 、 水 为溶剂， 以6.26 g (85%)的产率得到(S)-6,7-二甲氧基-1,2,3,4-四氢-3-异喹啉羧酸盐酸盐
  参考文献：
  名称：

  Chiral 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid and precursors

  摘要：

  本发明涉及光学纯的1,2,3,4-四氢异喹啉-3-羧酸化合物的L-(S)型式及其从可选纯的L-苯丙氨酸前体化合物制备的方法，以及利用新的原位阳离子催化剂系统制备它们的方法。

  公开号：

  US04912221A1

文献信息

• [EN] PREPARATION OF CHIRAL 1,2,3,4-TETRAHYDRO-6,7-DIALKOXY-3-ISOQUINOLINECARBOXYLIC ACID AND DERIVATIVES BY REACTING LEVODOPA WITH FORMALDEHYDE OR FORMALDEHYDE PRECURSORS<br/>[FR] PREPARATION D'ACIDE CHIRAL 1,2,3,4-TETRAHYDRO-6,7-DIALCOXY-3-ISOQUINOLINECARBOXYLIQUE ET DE SES DERIVES PAR LA REACTION DE LEVODOPA ET DE PRECURSEURS DE FORMALDEHYDE OU DE FORMALDEHYDE
  申请人：BRANTFORD CHEM INC

  公开号：WO2003101967A1

  公开（公告）日：2003-12-11

  A process for preparation of (S)-1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid compounds and their derivatives of the formula (1) the process compring: (i) reacting Levodopa of formula (2) with formaldehyde or formaldehyde precursors to obtain (S)-1,2,3,4-tetrahydro-6,7-dihydroxy-3-isoquinolinecarboxylic acid of formula (3); (ii) protecting the amino group of formula (3); (iii) alkylating the phenol groups of formula (4) to form compound of formula (5); and (iv) esterifying the carcoxylic acid of formula (5) and optionally removing N-protecting group wherein R1 is hydrogen, lower alkyl, C2-C12 acyl, or R1O together are methylenedioxy; R2 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, aralkyl or substituted aralkyl group; R3 is hydrogen, C2-C12 acyl group, benzyl, alkoxylcarbonyl group, or aralkoxyl carbonyl group; wherein P is the protecting group selected from alkoxycarbonyl, acyl, alkyl, aryl, siryl, sulfenyl and sulfonyl.

  一种制备(S)-1,2,3,4-四氢-6,7-二烷氧基-3-异喹啉羧酸化合物及其衍生物的方法，其化合物的结构式为(1)，该方法包括：(i)将结构式(2)的左旋多巴与甲醛或甲醛前体反应，得到结构式(3)的(S)-1,2,3,4-四氢-6,7-二羟基-3-异喹啉羧酸；(ii)保护结构式(3)的氨基团；(iii)烷基化结构式(4)的酚基，形成结构式(5)的化合物；以及(iv)酯化结构式(5)的羧基，并可选择去除N-保护基，其中R1为氢、较低烷基、C2-C12酰基，或R1O共同为亚甲二氧基；R2为氢、烷基、取代烷基、烯基、取代烯基、芳基、取代芳基、芳基烷基或取代芳基烷基；R3为氢、C2-C12酰基、苄基、烷氧羰基基团，或芳基烷氧羰基基团；其中P为从烷氧羰基、酰基、烷基、芳基、硫酰基和磺酰基中选择的保护基。
• Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types
  作者：Sylvester Klutchko、C. John Blankley、Robert W. Fleming、Jack M. Hinkley、Ann E. Werner、Ivan Nordin、Ann Holmes、Milton L. Hoefle、David M. Cohen

  DOI：10.1021/jm00160a026

  日期：1986.10

  The synthesis and angiotensin converting enzyme (ACE) inhibiting activities of quinapril (CI-906, 22), its active diacid (CI-928, 33), and its dimethoxy analogue (CI-925, 25) are reported. These tetrahydro-3-isoquinolinecarboxylic acid derivatives possess equivalent in vitro potency and in vivo efficacy to enalapril. Sulfhydryl analogues with the same structural variation are also highly potent. In

  据报道奎纳普利（CI-906，22），其活性二酸（CI-928，33）和其二甲氧基类似物（CI-925，25）的合成和血管紧张素转化酶（ACE）抑制活性。这些四氢-3-异喹啉羧酸衍生物具有与依那普利相当的体外效能和体内功效。具有相同结构变化的巯基类似物也非常有效。相反，四氢-1-异喹啉羧酸和同源异吲哚啉-1-羧酸类似物在两种类型的效力上显示出惊人的差异，巯基类似物基本上是无活性的，而非巯基类似物与脯氨酸原型是等效的。这是第一个证据表明小分子ACE抑制剂的两个主要结构类别可能存在其他结合模式。
• Tetrahydroisoquinolines as factor Xa inhibitors
  申请人：Song Yonghong

  公开号：US20060160840A1

  公开（公告）日：2006-07-20

  The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

  本发明涉及由公式I代表的化合物及其药学上可接受的盐、溶剂合物、水合物和前药，这些化合物是凝血因子Xa的抑制剂。本发明还涉及用于制备此类化合物的中间体，含有此类化合物的药物组合物，预防或治疗多种以不良血栓形成为特征的疾病的方法，以及抑制血样凝固的方法。
• WO2006/55951
  申请人：——

  公开号：——

  公开（公告）日：——
• Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors
  作者：William C. Patt、Harriet W. Hamilton、Michael D. Taylor、Michael J. Ryan、David G. Taylor、Cleo J. C. Connolly、Annette M. Doherty、Sylvester R. Klutchko、Ila Sircar

  DOI：10.1021/jm00092a006

  日期：1992.7

  A series of renin inhibitors was synthesized that contained a 2-amino-4-thiazolyl moiety at the P2 position. These derivatives are potent inhibitors of monkey renin in vitro and are selective in that they only weakly inhibit the closely related aspartic proteinase, bovine cathepsin D. Four compounds exhibited oral blood pressure lowering activity in high-renin normotensive monkeys. One of these compounds, 22 (PD 134672), was selected for further evaluation in renal hypertensive monkeys, on the basis of its superior efficacy and duration of action in the in vitro assays and the normotensive primate model.